Crista Biologics

3:00 PM - 4:00 PM (PDT), Wednesday, June 15, 2022

Crista Biologics delivers an innovative therapeutic platform to patients with refractory disease associated with mitochondrial abnormalities such as advanced heart failure, mitochondrial disease, sarcopenia/aging, and neurodegeneration disease. Mitochondria-rich extracellular vesicles (M-EVs) generated from iCMs contain healthy mitochondria and bioactive proteomes. M-EV-mediated mitochondrial transplantation therapy will restore the energy metabolism of the failing heart. We anticipate that this therapy will enhance the energetics of all cells in the human body.